Cara Therapeutics Inc (STU:69C)
€ 0.2506 -0.0086 (-3.32%) Market Cap: 14.16 Mil Enterprise Value: -22.43 Mil PE Ratio: 0 PB Ratio: 20.96 GF Score: 31/100

Cara Therapeutics Inc Research And Development Event (Virtual) Transcript

Mar 11, 2022 / 06:00PM GMT
Release Date Price: €10.95 (-0.64%)
Iris Francesconi;Investor Relations

Good afternoon, and welcome to Cara Therapeutics 2022 Virtual R&D Day.

Before we begin, let me remind you that today's presentation will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to update or revise the information provided on this webinar as a result of new information or future results or developments.

Participating from Cara today will be Chris Posner, Cara's President and Chief Executive Officer; and Dr. Joana Goncalves, Cara's Chief Medical Officer. We're delighted to also be joined by 2 highly accomplished key opinion leaders, Dr. Brian Kim; and Dr. Jonathan Silverberg. Dr. Kim is the Vice Chair of Research at the Icahn School of Medicine at Mount Sinai in New York; Site Chair

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot